<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04842539</url>
  </required_header>
  <id_info>
    <org_study_id>INT/IEC2018/2076</org_study_id>
    <nct_id>NCT04842539</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Transplantation in Decompensated Cirrhosis</brief_title>
  <official_title>Single Session of Fecal Microbiota Transplantation in Decompensated Cirrhosis: An Open-label Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Postgraduate Institute of Medical Education and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Postgraduate Institute of Medical Education and Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cirrhosis of the liver is the culmination point of long-standing chronic liver disease&#xD;
      hallmarked by the cardinal features of liver fibrosis and portal hypertension. The prognosis&#xD;
      of patients with cirrhosis is punctuated by the onset of complications which denote the stage&#xD;
      of decompensation characterized by ascites, hepatic encephalopathy (HE), and variceal&#xD;
      bleeding.&#xD;
&#xD;
      Patients with cirrhosis have been demonstrated to have significant changes in their gut&#xD;
      microbiota characterized by alteration in the intestinal microbiome (gut dysbiosis) as well&#xD;
      as small intestinal bacterial overgrowth (SIBO). Gut dysbiosis has been closely linked to the&#xD;
      complications associated with decompensated cirrhosis. Several studies have documented the&#xD;
      alteration of gut microbiota in patients with hepatic encephalopathy.&#xD;
&#xD;
      Therapeutic modalities that restore normal gut flora and stabilize the gut liver axis are&#xD;
      being extensively studied in the management of cirrhosis and its complications. Antibiotics,&#xD;
      probiotics, and long-chain fatty acid supplementation are being evaluated as methods to&#xD;
      restore the gut dysbiosis and consequently limit progressive liver damage.&#xD;
&#xD;
      Fecal Microbiota Transplantation (FMT) involves the infusion of intestinal microorganisms by&#xD;
      the transfer of stool from a healthy individual into a diseased individual for restoration of&#xD;
      normal intestinal flora.The ultimate goal of FMT is to replace aberrant native microbiota&#xD;
      with a stable community of donor microorganisms. The treatment is based on the premise that&#xD;
      an imbalance in the community of microorganisms residing in the gastrointestinal tract (i.e.,&#xD;
      dysbiosis) is associated with specific disease states. FMT has been well-established as a&#xD;
      treatment modality to stably modify the gut microbiome and has been shown to be safe and&#xD;
      efficacious in several disease states resulting from gut dysbiosis.&#xD;
&#xD;
      With this background, a trial is proposed to determine whether an FMT from a healthy donor to&#xD;
      a patient with advanced cirrhosis improves overall survival and prognosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Actual">November 30, 2019</completion_date>
  <primary_completion_date type="Actual">November 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>180 day</time_frame>
    <description>180 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Child Turcotte Pugh Score</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in MELD score</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in MELD Na score</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ammonia level</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interleukin level</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with incident Hepatic encephalopathy</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with incident Variceal Bleed</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>FMT Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FMT Arm:30 grams stool homogenized with 100 mL normal saline and filtered administered a single time via nasojejunal tube.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care (SOC) Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard of care treatment with nutritional supplementation and other supportive care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fecal Microbiota Transplantation</intervention_name>
    <description>In the Fecal Microbiota Transplantation procedure 100 ml volume of strained and filtered stool will be delivered through a nasojejunal tube.The recipient patient will be kept nil per oral for at least 4 hours prior to the stool instillation. 100 mL of freshly prepared stool suspension will be given.</description>
    <arm_group_label>FMT Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Nutritional supplementation and other supportive measures as per standard guidelines</description>
    <arm_group_label>Standard of care (SOC) Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Age 18-65 years Decompensated cirrhosis (of any etiology) based on clinical, radiological,&#xD;
        or histological criteria Model for end-stage liver disease (MELD scores) between 12-21 were&#xD;
        included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Ongoing bacterial infection requiring antibiotics Antibiotics/pre-pro biotics within the&#xD;
        last 14 days, t Significant alcohol intake in the previous two months, Recent (&lt;14 days)&#xD;
        history of spontaneous bacterial peritonitis, HE or variceal bleed, History of substance&#xD;
        abuse or psychiatric illness, HIV infection, Pregnant patients, Hepatocellular carcinoma or&#xD;
        other known malignancy, t Prior liver transplantation or bariatric surgery,&#xD;
        Immunosuppression, Inflammatory bowel disease Celiac disease, History of allergy to food&#xD;
        substances&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Post Graduate Institute of Medical Education and Research</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 3, 2021</study_first_submitted>
  <study_first_submitted_qc>April 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Postgraduate Institute of Medical Education and Research</investigator_affiliation>
    <investigator_full_name>Radha K Dhiman</investigator_full_name>
    <investigator_title>Professor of Hepatology</investigator_title>
  </responsible_party>
  <keyword>End-stage liver disease</keyword>
  <keyword>Stool therapy</keyword>
  <keyword>Microbiota</keyword>
  <keyword>Related stool donor</keyword>
  <keyword>Prognostic scores</keyword>
  <keyword>Complications</keyword>
  <keyword>Ammonia</keyword>
  <keyword>Cytokines</keyword>
  <keyword>Outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT04842539/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

